Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Predictors of Response to 13.3 mg/24 h Rivastigmine Patch in Patients with Severe Alzheimer's Disease
Aging, Dementia, and Behavioral Neurology
(-)
007
Authors/Disclosures
Martin R. Farlow, MD, FÂé¶¹´«Ã½Ó³»­ (Indiana University School of Medicine)
PRESENTER
No disclosure on file
Carl H. Sadowsky, MD, FÂé¶¹´«Ã½Ó³»­ No disclosure on file
Drew Velting, PhD (Novartis Pharmaceuticals Corp.) No disclosure on file
Xiangyi Meng, PhD (Novartis) Dr. Meng has nothing to disclose.
Nicolás Phielipp, MD, FÂé¶¹´«Ã½Ó³»­ (UCI Health, WEN center) The institution of Dr. Phielipp has received research support from Asklepius Biopharmaceuticals. The institution of Dr. Phielipp has received research support from Aspen Therapeutics.
No disclosure on file